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Puumala virus (PUUV) infection causes over 5000 cases of hemorrhagic fever in
Europe annually and can influence the hemostatic balance extensively. Infection might
lead to hemorrhage, while a recent study showed an increased risk of myocardial
infarction during or shortly after PUUV infection. The mechanism by which this
hantavirus influences the coagulation system remains unknown. Therefore we aimed to
elucidate mechanisms explaining alterations seen in primary and secondary hemostasis
during PUUV infection. By using low passage PUUV isolates to infect primary human
umbilical vein endothelial cells (HUVECs) we were able to show alterations in the
regulation of primary- and secondary hemostasis and in the release of fibrinolysis
regulators. Our main finding was an activation of secondary hemostasis due to
increased tissue factor (TF) expression leading to increased thrombin generation in
a functional assay. Furthermore, we showed that during infection platelets adhered
to HUVEC and subsequently specifically to PUUV virus particles. Infection of HUVEC
with PUUV did not result in increased von Willebrand factor while they produced
more plasminogen activator inhibitor type-1 (PAI-1) compared to controls. The PAI-1
produced in this model formed complexes with vitronectin. This is the first report that
reveals a potential mechanism behind the pro-coagulant changes in PUUV patients,
which could be the result of increased thrombin generation due to an increased
TF expression on endothelial cells during infection. Furthermore, we provide insight
into the contribution of endothelial cell responses regarding hemostasis in PUUV
pathogenesis.
Keywords: hantavirus, hemostasis, platelets, endothelial cells, thrombin generation, hemorrhagic fever with renal
syndrome, HFRS
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Introduction
Puumala virus (PUUV), a hantavirus carried by chronically
infected bank voles, is the causative agent of an estimated 5000
cases yearly of viral hemorrhagic fever in Europe (Vapalahti
et al., 2003; Vaheri et al., 2013a). Hantaviruses are rodent-borne,
negative stranded, RNA viruses belonging to the Bunyaviridae
family, which may cause two types of disease in humans
(Goeijenbier et al., 2013). In Europe and Asia, hantavirus infec-
tion causes hemorrhagic fever with renal syndrome (HFRS),
characterized by renal failure and bleeding complications. In
North and South America, hantavirus infection causes the
hantavirus cardiopulmonary syndrome (HCPS) where patients
present with severe acute respiratory distress (Sargianou et al.,
2012). Changing ecological factors determine ﬂuctuations in
hantavirus epidemiology resulting in sudden increases in inci-
dence, for instance through increased food availability, prolonged
virus survival and decreased biodiversity (Reusken and Heyman,
2013). Recent epidemiological studies reported an overall inci-
dence increase of PUUV infections in Europe (Heyman and
Vaheri, 2008).
Although PUUV infections have a low case fatality rate (<1%)
and in literature the virus is often described as the least vir-
ulent of the pathogenic viruses within the hantavirus genus,
PUUV infections can cause severe disease in healthy adults,
which may require a long recovery period lasting up to 1 year
(Schmaljohn and Hjelle, 1997). Furthermore, several reports
described cases with severe (hemorrhagic) complications like
pituitary gland hemorrhage, hematemesis and gastro-intestinal
bleedings (Eckerle et al., 2012; Antonen et al., 2013). In con-
trast to these bleeding complications, a recent study from Sweden
reported increased risk for acute myocardial infarction shortly
after PUUV infection (Connolly-Andersen et al., 2014). Given
the high incidence in Northern Europe, acute myocardial infarc-
tion as a complication of PUUV infection could have a major
impact in endemic areas. In light of both bleeding and thrombotic
events that might complicate PUUV infections, we hypothe-
sized that endothelial cells, also the target cells for hantaviruses
and the major regulators of coagulation and inﬂammation, play
a central role in the pathogenesis of the disease (Zhou et al.,
2003).
During hantavirus infection drastic alterations in the coagu-
lation system have been observed (Laine et al., 2014). Clinical
studies focusing on primary and secondary hemostasis dur-
ing hantavirus disease showed thrombocytopenia in both HFRS
and HCPS, a decreased plasma activity of coagulation factors
II, V, VIII, IX, and X in acute HFRS patients, prolongation
of the prothrombin and activated partial thromboplastin time,
increased thrombin generation andD-dimer levels and a decrease
in ADAMTS13 activity in acute PUUV patients (Lee, 1987;
Mackow and Gavrilovskaya, 2009; Laine et al., 2011; Mustonen
et al., 2013). The ability to infect endothelial cells by han-
taviruses has been demonstrated both in vitro and in vivo
(Yanagihara and Silverman, 1990; Pensiero et al., 1992; Toro
et al., 1998). Although infection does not lead to cytopathic
changes, several studies observed endothelial cell dysfunction
during hantavirus infection (Yanagihara and Silverman, 1990;
Pensiero et al., 1992; Mackow and Gavrilovskaya, 2009), rang-
ing from increased clinical markers of a stressed endothelium
in vivo (sICAM-1, VWF and circulating endothelial cells; Han
et al., 2010; Krautkramer et al., 2014), to increased permeabil-
ity and decreased HUVEC integrin ligand migration in vitro
(Gavrilovskaya et al., 2002; Geimonen et al., 2002; Taylor et al.,
2013).
Integrin ανβ3, experimentally proven to be the receptor for
hantavirus infection, is abundantly present on the surface of
endothelial cells (Gavrilovskaya et al., 1999; Song et al., 2005).
Infection with pathogenic hantaviruses is suggested to result in
the loss of function of the ανβ3 integrin (Wang et al., 2012),
but also an increased ανβ3 expression on cultured endothe-
lial cells and platelets has been observed (Liu et al., 2008).
Furthermore Gavrilovskaya et al. (2010) studied the adherence
of quiescent platelets to Sin Nombre and Hantaan virus infected
endothelial cells seems to be the result of virus binding to
the ανβ3 integrin present on platelets (Gavrilovskaya et al.,
2010).
How the abnormalities in the primary (thrombocytopenia)
and secondary hemostasis (increase in thrombin generation
and raised D-Dimer levels) are induced in PUUV infected
patients and the mechanism by which Old-World hantaviruses
cause hemorrhage and/or renal failure remain largely elusive
(Vaheri et al., 2013b). Lack of speciﬁc treatment and an eﬀec-
tive vaccine makes understanding of the pathophysiology of
hantavirus infection an important medical need, especially with
the recently discovered association of PUUV with cardiovas-
cular disease (Connolly-Andersen et al., 2014). Therefore, we
have used an integrated approach to study changes in primary
and secondary hemostasis using an in vitro endothelial cell
model.
Materials and Methods
Cells
VeroE6 cells (American Type Culture Collection, USA) were
grown in Dulbecco’s Modiﬁed Eagle Medium (DMEM) con-
taining 10% fetal bovine serum (FBS, Lonza, the Netherlands),
100 U/ml penicillin-streptomycin solution, 1% Hepes buﬀer and
1% sodium bicarbonate (all from Gibco, Life Sciences, USA).
Human umbilical vein endothelial cells (HUVECs) were har-
vested from umbilical veins, which were kindly provided by
Erasmus MC birth center. Brieﬂy, umbilical cords were stored
in sterile 500 ml PBS supplemented with gentamycin (50 μg/ml;
Leo Pharmaceutical, Denmark). Veins were rinsed with PBS con-
taining 50 U/ml heparin (Leo Pharmaceutical). Subsequently,
cells were detached with 0.1% collagenase solution (C6885,
Sigma Aldrich, USA). Cell suspension was collected in a sterile
50 ml tube followed by two times centrifugation (5 min 300 g).
The cell pellet was re-suspended in HUVEC medium (human
endothelial-SFM medium; Invitrogen, Life Sciences, USA) con-
taining 10% human serum (Lonza), 20% ﬁltrated FBS (Lonza);
penicilin/streptomycin 100 U/ml, 20 ng/ml ﬁbroblast growth fac-
tor (Peprotech, USA) and 10 ng/ml of endothelial cell growth
factor (Peprotech). HUVEC cell suspensions were cultured in
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ﬂasks pre-coated with 20 μg/ml of ﬁbronectin (Roche, the
Netherlands). Only cells up to passage four, from one speciﬁc
donor, were used for this study. Identity of the endothelial cells
was conﬁrmed by ﬂow cytometry using Ulex europeus lectin,
anti-CD31 and Von Willebrand Factor (VWF) staining and
immunoblot.
Anti-Sera
We made use of the following antibodies and conjugates: poly-
clonal rabbit anti- VWF, HRP labeled polyclonal goat anti-
rabbit IgG and polyclonal rabbit anti-mouse (All from Dako,
the Netherlands). FITC labeled monoclonal anti-CD31 (Sigma
Aldrich, USA), polyclonal rabbit anti-CD41 (Perbio Science,
the Netherlands), polyclonal rabbit anti-CD3 (Dako), poly-
clonal rabbit anti-PUUV nucleoprotein (BEI Resources, USA),
monoclonal anti-PUUV glycoprotein (HY Test, Finland), mon-
oclonal anti-ανβ3 integrin (Abcam, UK), monoclonal anti-
vitronectin (Novus Bio, USA), polyclonal rabbit-anti PAI-1 (Bio
Connect, the Netherlands), polyclonal rabbit anti-tissue factor
(TF; Bio Connect), human serum from a recovered PUUV case
described in Goeijenbier et al. (2011) retrieved after informed
consent and ethical board approval. Antibodies and conjugate
were diluted in dilution buﬀer, which consisted of PBS with
0.5% bovine serum albumin, 2% NaCl and 1% normal goat
serum.
Virus Infection
Virus Isolation
Lungs of Myodes glareolus from Konnevesi, Finland, infected
with PUUV were homogenized in DMEM (10% w/v) and 100 μl
was added onto a 70–80% monolayer of VeroE6 cells and incu-
bated for 60 min at 37◦C in 5% CO2. The supernatant was
discarded and cells were washed three times and incubated with
fresh veroE6 medium for an additional 5 days. Virus stocks up
to passage four were created by centrifugation (10 min 400 g)
of the supernatant to create a cell free virus stock. Virus titer
was determined using immune peroxidase reaction (IPOX) and
TCID50 was calculated using the Karber formula (Kärber, 1931).
Infectious virus was inactivated using beta-propiolactone (BPL;
Sigma Aldrich, USA; 1:4000 v/v) at 4◦C for 24 h. Subsequently,
BPL was inactivated for 1 h at 37◦C. All virus stocks were
stored at −80◦ until use. All experiments were conducted under
biosafety instructions required regarding work with live PUUV.
Vesicular stomatitis virus (VSV) strain Indiana, propagated also
on VeroE6 cells, was kindly provided by Dr. Bart Haagmans
(Erasmus MC).
Infection Kinetics and Dynamics
Human umbilical vein endothelial cell were seeded into 24-
well- (2.4 × 105 cells) or 96-well plates (4 × 104 cells; Corning,
USA) depending on the experiment. Conﬂuent monolayers were
infected with a multiplicity of infection (MOI) of 0.5 or 3, with
infectious and inactivated (BPL-inactivated) virus or a normal
medium control for 60 min at 37◦C in 5% CO2. After incuba-
tion, the supernatant was discarded and cells were washed three
times with RPMI 1640 (Gibco, Life Sciences). Fresh medium was
added as described earlier. For VWF and plasminogen activator
inhibitor type-1 (PAI-1) quantiﬁcation, medium did not contain
FCS but was supplemented with 4% sterile ﬁltered bovine serum
albumin (BSA, Sigma Aldrich, USA) to avoid addition of fetal calf
VWF and PAI-1 (Zoellner et al., 1996). To quantify the percent-
age of infected cells we used an in house developed IPOX pro-
cedure. HUVEC were washed three times with PBS. Cells were
ﬁxed with absolute −20◦Cmethanol and incubated at−20◦C for
30 min. After ﬁxation, methanol was discarded and cells were
incubated for 30 min at 37◦C with 100 μl of 0.05% H2O2 in
PBS, to block endogenous peroxidases. Subsequently, cells were
washed three times with PBS and incubated for 60 min with poly-
clonal rabbit anti-PUUV nucleoprotein antibody (1:500). Cells
were washed with PBS 0.05% tween followed by incubation with
HRP-labeled goat anti-rabbit IgG conjugate (1:500). Color devel-
opment was achieved by addition of 3-amino-9-ethylcarbazole
(AEC) substrate (AEC dissolved in dimethylformamide buﬀered
with acetate buﬀer of pH 5). Percentage of infected cells was
determined by manual counting.
For the quantiﬁcation of viral replication we used a stan-
dard line of in house generated PUUV RNA run-oﬀ tran-
scripts, as described for West-Nile virus (Lim et al., 2013).
Brieﬂy, RNA run-oﬀ transcripts were generated using a seg-
ment ampliﬁed with pan-hantavirus degenerative PCR primers
from (Johansson et al., 2010). PCR products were separated
on 1% agarose gel and bands of correct size were collected
for DNA gel extraction using the MinElute Gel Extraction
Kit Protocol (Qiagen, USA). DNA fragments were cloned into
the pCR4 vector using the TOPO TA Cloning KIT (Life
Technologies) and One Shot TOP10 chemically competent
Escherichia coli were transformed with the recombinant vec-
tor (QIAGEN) according to manufacturer’s protocol. At least
ﬁve colonies were collected for further analyses. Plasmid DNA
was puriﬁed using MinElute DNA puriﬁcation kit (QIAGEN).
Plasmid DNA was linearized by restriction digestion (NotI for
the negative strand RNA and PstI for the positive strand RNA).
Run-oﬀ transcripts (in vitro transcripts) were synthesized using
T3 RNA polymerase for negative strand and T7 RNA poly-
merase for positive strand (MEGAscript T3 and T7 tran-
scription kits, Life technologies), followed by DNase treatment
(Ambion TURBO DNA-freeTM Life Technologies), according
to manufacturer’s manual. The amount of RNA in the stock
was determined using NanoDrop and serially diluted. Copy
numbers in the standards were calculated using RNA concen-
tration and sequence length with help of an online calculator
(http://endmemo.com/bio/dnacopynum.php).
Platelet Binding Assay
Platelet Collection
To study interaction between PUUV and platelets, platelets were
collected according to the protocol described in Gavrilovskaya
et al. (2010) with minor modiﬁcations. Brieﬂy, blood was col-
lected in 0.105 M (end concentration) sodium citrate tubes
(BD-plymouth, UK) supplemented with 1 μM prostaglandin E1
(Cayman Chemical, USA) to block platelet activation. Platelet-
rich plasma (PRP) was prepared by centrifugation for 15 min at
700 × g at 25◦C. Subsequently, platelets were pelleted for 15 min
at 1300× g at 25◦C. Platelets were washed twice and resuspended
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with modiﬁed hepes buﬀer (25 mM Hepes, 137 mM NaCl, 0.1%
Albumin and 1 μM prostaglandin E1 pH 7.4) and counted by a
hematocytometer.
Platelet HUVEC Binding
Platelets (108 per ml) were incubated with infected HUVEC (96
wells plate; PUUV, BPL inactivated PUUV or mock control)
for 30 min at 37◦C. After incubation, monolayers were washed
three times with RPMI and cells were ﬁxed with formalin. After
ﬁxation, formalin was discarded and cells were incubated for
30 min at 37◦C/5% CO2 with PBS 0.05% H2O2. After three
washing steps cells were incubated with rabbit polyclonal anti-
human CD41a antibody (1:500). The following steps were as
described earlier for IPOX. After incubation with HRP-labeled
goat anti-rabbit conjugate (1:1000) TMB was added to the wells
for substrate reaction. After 10 min reaction was stopped by
addition of 0.5 M sulphuric acid and optical density (OD) was
measured at 450 nm using Tecan ELISA reader. CD41a expres-
sion OD was calculated by subtracting the blanc OD value (wells
incubated without platelets but with detection antibody and con-
jugate). Rabbit polyclonal anti-CD3 (1:500) served as an isotype
control.
Platelet PUUV Binding
To test if changes in CD41a expression was related to direct
binding between PUUV and platelets, a mechanism shown
in Hantaan and Andes virus infection (Gavrilovskaya et al.,
2010), a pull down assay was designed. To this end, we ﬁrst
coated ELISA plates with PUUV or a control virus (VSV;
100 μl of 106 virus particles in DMEM at 4◦C overnight)
followed by platelet incubation (107 platelets). Subsequently,
cells were washed ﬁve times with PBS and the bound platelets
were quantiﬁed by using a platelet detection antibody (anti-
CD41a 1:500 in dilution buﬀer) followed by a conjugate sub-
strate reaction. CD41a expression was calculated by subtrac-
tion of the OD measured in the wells without platelet incu-
bations (blanco) to correct for direct (a-speciﬁc) anti-CD41a
antibody binding to PUUV and anti-CD3 was used as isotype
control. Subsequently, ELISA plates were coated with mouse
monoclonal anti-PUUV glycoprotein- or isotype control anti-
body (IgG2 corona virus; 1:500 in PBS at 4◦C overnight)
followed by incubation with PUUV to capture the virus fol-
lowed by platelet incubation, detection antibody and conjugate
substrate reaction. Thirdly, to further conﬁrm platelet PUUV
binding, ELISA plates were coated with an anti-platelet anti-
body (1:500 in PBS at 4◦C overnight), followed by incubation
with fresh isolated platelets and eventually an incubation step
with PUUV or VSV followed by a hantavirus detection anti-
body (mouse mAB anti-PUUV-glycoprotein 1:500). After wash-
ing substrate reaction was achieved by conjugate addition and
TMB reaction steps. As a ﬁnal step we studied the potential
blocking of platelet binding by PUUV particles by the addi-
tion of a blocking step with polyclonal human anti PUUV
serum. PUUV coated plates and plates coated with 5 days old
virus free VeroE6 medium were incubated with a polyclonal
PUUV serum (1:50) from a case described in Goeijenbier et al.
(2011) or with a PUUV IgG negative control human serum
from a healthy volunteer (also 1:50). The following platelet bind-
ing steps and CD41 detection were the same as in the earlier
experiments.
Von Willebrand Factor and Plasminogen
Activator Inhibitor Type-1 Quantification
After infection, in a 24-well plate, supernatants (500 μl) were
subsequently removed and cells were lysed, after three washing
steps, using a 15min incubation with 500μl PBS 1% TritonX-100
followed by centrifugation (10 min 400 × g). Cell-free super-
natants and supernatant from cell lysates were measured using
a PAI-1 antigen and VWF ELISA kits according the manu-
facturer’s instructions (both from Zymugen, Hyphen Biomed,
France).
Tissue Factor Expression and Activity
Tissue Factor Cell Surface Expression
Human umbilical vein endothelial cell in 96 wells plates were
ﬁxed with 4% formalin and incubated with rabbit polyclonal anti-
TF antibody (1:500) followed by incubation with the respective
conjugate (1:500). After washing TMB was added for substrate
reaction and reaction was stopped after 10 min by addition of
0.5Mof sulphuric acid. OD 450 nm valuewasmeasured on Tecan
ELISA reader.
Tissue Factor Cell Lysate Concentration
Cell lysates were prepared as described in Section “Von
Willebrand Factor and Plasminogen Activator Inhibitor Type-
1 Quantiﬁcation.” ELISA plates were coated with a mixture of
50 μl cell lysate and 50 μl PBS over night at 4◦C together
with a standard curve of recombinant TF (Innovin; Siemens
Healthcare Diagnostics, Germany). After blocking wells were
incubated with rabbit polyclonal anti-TF antibody (1:500) fol-
lowed by incubation with the respective conjugate (1:500).
After washing TMB was added for substrate reaction and reac-
tion was stopped after 10 min by addition of 0.5 M of sul-
phuric acid. OD 450 nm value was measured on Tecan ELISA
reader.
Thrombin Generation
Thrombin generation in platelet-poor plasma (PPP) was mea-
sured directly on HUVEC surface, in a 96 well plate, by recal-
ciﬁcation of 80 μl of pooled citrated plasma from healthy
donors added to the monolayer of infected and uninfected
cells. In summary, cells were washed three times with RPMI
and 80 μl freshly thawed plasma was added to the mono-
layer together with 60 μl of HEPES buﬀer (25 mM Hepes,
137 mM NaCl, 0.1% albumin). On the same plate a serial
dilution of recombinant TF (Innovin; Siemens Healthcare
Diagnostics, Germany) in the absence of cells. Finally, 60 μl of
HEPES calcium [25 mM Hepes, 137 mM NaCl, 0.1% Albumin,
38 mM CaCl(2)] was added to plasma. Directly after recal-
ciﬁcation, OD 450 nm value was measured using a Tecan
ELISA reader in a kinetic cycle measuring every 45 s for 1 h.
Thrombin generation time was deﬁned as the time at half-
maximal OD.
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Vitronectin – PAI-1 Complex Levels
ELISA plates were coated with anti-vitronectin antibody (1:500
in PBS at 4◦C overnight), incubated with supernatant from
PUUV infected or non-infected HUVEC followed by incuba-
tion with polyclonal anti-PAI-1 antibody (1:500) and subsequent
conjugate-substrate reaction. PBS incubation was used as a blanc
control and anti-CD3 antibody (1:500) incubation as an isotype
control.
Statistics
All statistical analyses were performed using GraphPad Prism
5.01 for Windows. When comparing two groups we made
use of a Student’s t-test or Mann–Whitney U, depending on
the distribution of the data. For the comparison between
multiple groups non-parametric Kruskal-Wallis test was used
with Dunn’s multiple comparison test or a one-way ANOVA
with Tukey’s multiple comparisons test, depending on the
distribution of the data. P ≤ 0.05 were considered signiﬁ-
cant.
Results
PUUV Infects and Replicates in Primary
Endothelial Cells
To prevent PUUV from in vitro loss of virulence, virus stocks
of not more than four passages were prepared. Freshly isolated
HUVEC were infected with MOI 0.5 and 3. The PUUV infected
and replicated in HUVEC, as is summarized in Figure 1. Non-
infected cells (Figures 1A,B) showed no red peroxidase staining,
conﬁrming speciﬁcity of the PUUV-staining. From 24 h post
infection with a low MOI infection (0.5) onward (Figure 1C)
FIGURE 1 | Puumala virus (PUUV) immune peroxidase (IPOX) staining
and viral copy numbers after infection with a multiplicity of infection
(MOI) of 0.5 and 3. Mock infected cells (A,B) showed no red peroxidase
staining for PUUV nucleoprotein after 24 (A) and 48 (B) hours. Twenty-four
hours after infection with MOI 0.5 (C) a small number of cells stained positive,
which, increased at 48 h (D). Infection with MOI 3 resulted in more infected
cells after 24 h (E), which increased slightly at 48 h post infection (F). Analysis
of viral replication showed a more than 2-log increase of viral copy numbers in
both supernatant (G) and cell lysates (H), suggesting active viral replication.
Bars represent SE of the mean. BPL inactivation of the virus lead to no
increase in viral copy numbers in the supernatant and a negative IPOX staining
(data not shown). Furthermore infection was confirmed by western blot for the
presence of the PUUV nucleoprotein in the cell lysate and Von Willebrand
Factor (VWF) to confirm the character of the endothelial cells (I). The first four
lanes show control wells with only one band present at the upper side of the
blot (VWF). The last for lanes show the presence of both VWF and the PUUV
nucleoprotein (∼55 kDa 10ug/lane). Data are representative of three
independent experiments.
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only a small percentage (±10%) of the cells were infected, which
strongly increased after 48 h (Figure 1D), resulting in 50% of
infected stained cells. Twenty-four hours after infection at a
MOI of 3 about 40–50% of cells were infected (Figure 1E),
which increased further to 80% by 48 h (Figure 1F). Comparable
kinetics were seen when viral RNA copy numbers were deter-
mined. To this end, viral RNA numbers were estimated both in
supernatant (Figure 1G) and cell lysate (Figure 1H). At both
MOIs the number of viral RNA increased signiﬁcantly (2-Log)
after 48 h (Kruskal-Wallis; p = 0.0028), in the supernatant as
well as in the cell lysate, conﬁrming active viral replication. Viral
replication reached a plateau at 72 h post infection.
Furthermore western-blot analysis of the cell lysate for PUUV
nucleoprotein conﬁrmed infection of HUVEC (Figure 1I). The
viral copy numbers in the supernatant or cell lysate of HUVEC
incubated with BPL inactivated virus served as a control for non-
replicating virus. Consistently, the RNA copy numbers did not
increase over time indicating the eﬃcient inactivation of the virus
by BPL treatment. Eﬃcient inactivation was conﬁrmed by nega-
tive IPOX staining of the HUVEC incubated with BPL inactivated
PUUV (data not shown).
Increased CD41a Expression after
Incubation of Platelets on HUVEC upon
PUUV Infection
Gavrilovskaya et al. (2010) reported the potential of Hantaan and
Andes virus to bind quiescent platelets via ανβ3 integrin. Since
this observation is of much importance in further understand-
ing the alterations in primary hemostasis and its role in disease
mechanisms in HFRS we decided to conﬁrm this mechanism for
PUUV using a diﬀerent approach. First we assessed the ability of
quiescent platelets to bind to PUUV infected HUVEC (Figure 2).
Binding of platelets was determined by measuring the intensity
of CD41a (platelet glycoprotein IIb), a heterodimeric integral
membrane protein present only on platelets and megakary-
ocytes. CD41a expression was signiﬁcantly higher on the HUVEC
monolayer after infection with a MOI of 0.5, or 3 compared to
the control. Detection of CD41a expression did not diﬀer when
platelets were not added to the HUVEC monolayers, suggesting
that there was no non-speciﬁc anti-CD41a binding to infected
cells. Furthermore there was no diﬀerence in OD values when an
isotype control (anti-CD3) was used to detect platelets. Based on
CD41a expression, statistically signiﬁcant diﬀerences were mea-
sured between infected wells and wells incubated with virus free
VeroE6 medium (negative control) at 24 h post infection (one
wayANOVA,MOI 3 vs. NEG p< 0.01,MOI 0.5 vs. Neg p< 0.05).
After 48 h of infection this diﬀerence in CD41a expression was
also signiﬁcant between MOI 3 infected wells and the BPL inacti-
vated virus control (one way ANOVA, MOI 3 vs. NEG p < 0.001
and MOI 3 vs. BPL p< 0.001; MOI 0.5 vs. NEG p< 0.05). Taken
together, the data indicate that platelets bind to cultures incu-
bated with PUUV. HUVEC incubated with BPL did show a trend
to increased platelet CD41a expression (Figure 2), but this was
not statistically signiﬁcant.
Von Willebrand Factor (VWF) is not
Increased During PUUV Infection of HUVEC
We measured VWF antigen in cell free supernatant and VWF
expression on the surface of infected HUVEC. Increased VWF
production may be a general inﬂammatory response of endothe-
lial cells that could be evoked as a result of PUUV infection.
However, at the time points where platelet binding increased,
HUVECs infected with PUUV showed no alteration in VWF
activity, as determined by ELISA, in neither the supernatant nor
the cell lysate (data not shown) compared to BPL or negative
control.
Platelets Bind Directly to PUUV
Next we looked whether the platelets could bind directly to
PUUV particles. For this purpose we performed an in-house
developed platelet pull down-assay using quiescent platelets. To
this end, several experiments were conducted to demonstrate
speciﬁcity of this binding. Figure 3 shows results of binding of
platelets to virus-coated ELISA plates (Figure 3A). More platelets
FIGURE 2 | Increased platelet binding to PUUV infected HUVEC.
Increased optical density (OD) of CD41a was measured both 24 (A) and 48 (B)
hours after infection with both low and moderate MOI and platelet incubation on
HUVEC surface. p values (*p < 0.05, **p < 0.01, ***p ≤ 0.001) are the result of
one way ANOVA testing with Tuckey’s multiple comparison posttest. Bars
represent the SE of the mean. Incubation with an isotype control antibody
(polyclonal anti-CD3) did not lead to increased OD on infected or control
HUVEC. Data are representative of three independent experiments.
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FIGURE 3 | Puumala virus and platelets bind to each other. In a pull
down assay platelets adhere better to PUUV virus particles compared to
vesicular stomatitis virus (VSV; A; Mann–Whitney U p = 0.0022). When virus
was captured with a PUUV glycoprotein antibody (B), platelets were able to
bind to the captured virus, in contrast to wells coated with an IgG2 control
antibody (anti-coronavirus glycoprotein; Mann–Whitney U p = 0.0022),
resulting in no capture of PUUV during the incubation process, controlling for
potential other factors present in the virus stock medium. When platelets
were bound to plates coated with an anti-CD41a antibody (C), the PUUV
particles were able to bind to platelets based on the significant increase in
PUUV detection OD compared to wells incubated with VSV particles, thus no
PUUV present (Mann–Whitney U p = 0.0043). The binding between PUUV
and platelets could be blocked by the addition of a blocking step with
human anti-PUUV serum (D) which show a decreased CD41 expression
when compared to the PUUV coated wells incubated with a PUUV negative
control serum. In all experiments no difference in OD was measured when an
isotype control antibody was used. Data are representative of three
independent experiments. ∗∗p < 0.01, ∗∗∗p ≤ 0.001.
(Mann–Whitney U; p= 0.0022) adhered to plates directly coated
with PUUV compared to plates coated with a virus control
(VSV), which was cultured under the same conditions as PUUV.
Subsequently, to control if the binding of platelets was directly
to the PUUV particles and not due to another factor present in
the VeroE6 supernatant we made use of a sandwich ELISA prin-
ciple. PUUV was incubated on ELISA plates with wells coated
with a monoclonal IgG2 speciﬁc for the glycoprotein of PUUV or
with a IgG2 control antibody. By this approach signiﬁcantly more
platelets bound to the wells where PUUVwas captured compared
to wells with no PUUV capture (Mann–Whitney U; p = 0.0022;
Figure 3B).
To conﬁrm direct binding between platelets and PUUV,
platelets were captured to anti-CD41 coated ELISA plates and
incubated with virus followed by detection with a PUUV speciﬁc
antibody. To control for binding between PUUV detection anti-
body and captured platelets, control wells were incubated with
VSV. PUUV detection was signiﬁcantly higher in the wells
incubated with PUUV compared to VSV (Mann–Whitney U;
p = 0.0043; Figure 3C). These experiments collectively suggest
that platelets can speciﬁcally bind to PUUV.
Finally, we show in Figure 3D that the binding of platelets
to PUUV particles could be blocked by addition of a blocking
step with human serum from a recovered PUUV case. When
wells coated with PUUV were incubated with human serum
with proven PUUV neutralizing IgG antibodies signiﬁcantly less
platelets adhered to the wells compared to wells incubated with
a PUUV negative human control serum (Figure 3D; p < 0.001).
The anti-CD41 expression in the wells with a blocking step was
comparable to that of the negative control, which consisted out of
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FIGURE 4 | Puumala virus infection of HUVEC induces tissue factor
expression resulting in enhanced thrombin generation. MOI 3 infection
resulted in increased TF expression (A, Mann–Whitney U p = 0.0002) on
HUVEC surface after 48 h (A) and in the cell lysate (B). Thrombin generation
time (TGT) was significantly decreased, indicating more thrombin formation, for
cells infected with PUUV (MOI 3) at 24 (C) and 48 (D) hours post infection (one
way ANOVA; 24 h p < 0.01 and 48 h p < 0.001). Results are shown with
whiskers from minimum to maximum. MOI 0.5 infection resulted in shortened
TGT 48 h post infection (one way ANOVA p < 0.001). Mean tissue factor (TF)
concentration, calculated from TGT standard curve, increased more than
ninefold after MOI 3 infection (one way ANOVA 24 and 48 h p < 0.01). MOI 0.5
infection increased TF concentration threefold after 48 h (one way ANOVA
p < 0.05; E, F; bars represent SE of the mean). Data are representative of three
independent experiments. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p ≤ 0.001.
plates coated with 5 days old vero E6 virus free medium. Binding
of the neutralizing IgG antibodies was conﬁrmed by incubation
with a goat-anti human HRP labeled conjugate and subsequent
TMB reaction.
Increased Thrombin Generation and Tissue
Factor Expression after PUUV Infection of
HUVEC
To test the hypothesis whether increased thrombin generation
observed in acute PUUV patients is the result of increased TF
expression on endothelial cells we incubated HUVEC, infected
with PUUV at a MOI of 3 or with a virus free 5 days old Vero
E6 medium (control) with a polyclonal anti-TF antibody. By
this approach we showed that TF expression was signiﬁcantly
increased with an almost twofold increase in OD value 48 h
post infection (Figure 4A, Mann–Whitney U; p = 0.0047). Cells
infected with PUUV also showed an increased TF concentration
when the cell lysates of PUUV infected wells were compared to
the lysates of control wells (Figure 4B; both mock and BPL).
Subsequently we wanted to prove that the increase in TF expres-
sion on the endothelial cell surface was of biological signiﬁcance
and would led to increased thrombin generation. Thrombin
generation was quantiﬁed directly on infected endothelial cells by
incubating normal plasma on cells and initiating coagulation by
the addition of calcium ions. Infected cells induced plasma clot-
ting faster due to increased thrombin generation (Figures 4C,D).
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FIGURE 5 | Plasminogen activator inhibitor type 1 production, surface
expression of ανβ3-integrin and PAI-1 vitronectin complex formation in
HUVEC infected with PUUV. Total plasminogen activator inhibitor type-1
(PAI-1) concentration was significantly increased on time points 48 post PUUV
infection (black; one way ANOVA, p < 0.05; A) compared to BPL inactivated
control (gray) or negative medium control (white). Panel B shows the PAI-1
vitronectin complex levels in HUVEC infected with PUUV (black) or non-infected
controls (white). After 48 h of infection PAI-1 vitronectin levels were increased
compared to the mock infection (Mann–Whitney U p = 0.03; B). Data are
representative of three independent experiments. ∗p < 0.05.
Using a calibration curve with puriﬁed TF in the absence of
endothelial cells, we quantiﬁedHUVECTF production after virus
infection and after incubation with a virus free medium control.
TF concentration showed a statistically signiﬁcant increase for
MOI 3 at 24 h compared to the negative control and the HUVEC
infected with MOI 0.5 (one way ANOVA; p < 0.01) and at
48 h post infection compared to the negative control (one way
ANOVA; p < 0.001). The MOI 0.5 infection led to higher levels
of TF on the HUVEC surface only after 48 h post infection (one
way ANOVA; p< 0.05) when compared to mock.
Increased Levels of PAI-1 and
PAI-1-Vitronectin Complexes in HUVEC
Supernatant after Infection with PUUV
Important proteins in the regulation of ﬁbrinolysis show close
interactions with the pathogenic hantavirus receptor ανβ3 inte-
grin. For instance vitronectin, a stabilizer of PAI-1 activity
in plasma, is largely regulated by this receptor (Mackow and
Gavrilovskaya, 2009; Florova et al., 2013). To study potential
changes in regulators of ﬁbrinolysis we ﬁrst measured PAI-
1 levels in the cell-free supernatant and supernatant of cell
lysate from 24-well plates infected with PUUV or control infec-
tions. The total PAI-1 antigen (the combination of levels in
the supernatant and cell lysate) was signiﬁcantly increased
48 h post infection (Kruskal–Wallis; p < 0.05) with MOI 3
(Figure 5A). Subsequently, we tested if in our model PAI-1
would bind to vitronectin, since this binding is associated with
increased/prolonged PAI-1 activity (Seiﬀert and Loskutoﬀ, 1991),
and if this interaction is altered during infection. ELISA plates
coated with a monoclonal antibody against vitronectin, incu-
bated with supernatant from our experiments (pooled, control or
from MOI 3 infected wells) followed by incubation with PAI-1
antibody suggested formation of PAI-1 vitronectin complexes
due to an increase in OD compared to incubation with PBS
(mean expression in medium 490 mOD (±100) vs. 370 mOD
(±70) p = 0.02). If supernatants were tested separately (PUUV
vs. mock) levels of PAI-1 vitronectin complexes were increased
after PUUV infection (Mann–Whitney U; p = 0.03; Figure 5B).
Discussion
The present study addresses platelet binding to PUUV infected
cells and activation of secondary hemostasis after endothelial cell
PUUV infection. With the lack of a valid and accessible animal
model for old-world hantavirus infection, we remain dependent
on ex vivo cell culture models to address questions regarding viru-
lence and pathogenesis (Vaheri et al., 2013b). Taking into account
the recently found association of PUUV infection with cardiovas-
cular disease (Connolly-Andersen et al., 2014) and hemorrhagic
complications that may occur during infection, the interaction
between PUUV and the coagulation system especially warrants
further attention. Since PUUV tends to rapidly lose virulence
upon in vitro cell passages the use of low passaged isolates is of
vital importance (Nemirov et al., 2003). Therefore, we have put
a lot of emphasis on obtaining low passage PUUV isolates and
optimisation of the hemostatic assays under the right biosafety
regulations using primary cell cultures.
Based on hemostatic changes seen in several clinical stud-
ies, most from Northern Europe, we decided to study speciﬁc
parts of the coagulation system in vitro. We started by study-
ing the eﬀects of PUUV infection on formation of a platelet
plug, the major event in primary hemostasis. Binding of platelets
by PUUV infected cells could explain thrombocytopenia in
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acute PUUV patients, since it would result in wasting or loss
of platelets adhered to these cells (Gavrilovskaya et al., 2010;
Laine et al., 2011). Especially if we make notice of the abil-
ity of hantaviruses to infect megakaryocytes and thereby lead
to a decreased production of platelets, in addition to the loss
of platelets adhered to infected cells (Liang et al., 2004; Lutteke
et al., 2010). In our model it seems that PUUV infection increases
binding of platelets to the surface of HUVEC compared to
control cells (Figure 2). Here we assumed increased CD41a
expression observed in the ﬁrst experiments was the result of
an increased number of platelets on the HUVEC. Theoretically,
increased CD41a detection could also be due to an increased
expression of CD41a on platelets, after 30 min incubation with
infected HUVEC, rather than an actual increase in platelet
numbers. While we cannot rule this out based on our experi-
ments, we blocked extrinsic platelet activation by prostaglandin
treatment making platelet activation less likely. Furthermore,
in line with studies performed with more pathogenic han-
taviruses (Gavrilovskaya et al., 2010), we tested speciﬁc bind-
ing of platelets to PUUV particles. Judged from results from
the platelet pull down experiments (Figure 3) this seemed to
be a speciﬁc binding between virus and platelets which could
be reversed by the addition of PUUV neutralizing antibod-
ies. In these experiments we controlled for aspeciﬁc binding
of antibodies (isotype control experiments), factors present in
the virus culture medium (5 days old VeroE6 medium as a
control) and binding of platelet detection antibody directly to
PUUV.
We expected the increased platelet binding to co-occur with
increased VWF production, as a general inﬂammatory response
during infection. However, the observation that VWF concentra-
tion does not change during PUUV infection, further suggested
a VWF-independent mechanism for platelet binding in HFRS.
Results from earlier studies showed an increased VWF con-
centration in hospitalized PUUV patients (Laine et al., 2011).
One should keep in mind that overall plasma VWF level in any
patient represents the state of the total endothelial cell layer
and not only that of infected cells, as is the case in our model.
Furthermore we are studying the acute response of endothe-
lial cells in the ﬁrst 48 h after infection, a time point at which
PUUV patients are generally not considered to be hospitalized
and tested. The increase of VWF in all three conditions (con-
trol, BPL and PUUV) over time in our HUVEC model could be
the result of an increased number of cells or a sign of in vitro
stress and activation of the endothelial cells. Since it seems highly
unlikely the cells still multiply after the formation of a full mono-
layer, which is present at the time of infection, we believe that
also non-infected cells show a certain level of activation when in
culture.
Gavrilovskaya et al. (2010) were the ﬁrst to study the inter-
action of hantaviruses (Andes and Hantaan) with platelets, and
concluded that there was a speciﬁc binding of Hantaan and
Andes virus particle particles to ανβ3 integrins present on
both endothelial cells and platelets. Interestingly, our experi-
ment showed a trend to increased number of platelets bound
to the BPL-inactivated virus treated cultures, suggesting active
replication was unnecessary and inactivated virus, bound to the
cell surface, might also bind to integrins present on platelets.
However, this hypothesis is merely based on a statistical trend
observed in wells with the cells incubated with BPL inactivated
virus. For the interpretation of our data one should take in
mind that we made use of a MOI 3 BPL at t = 0 h and that
the BPL inactivated virus will not replicate. Therefore at time-
point t = 24 and t = 48 the BPL control will most likely be
comparable to the MOI 0.5 infection. It could very well be
the case that when increasing the MOI for the BPL infection
a more comparable result to the MOI 3 infection would be
observed.
Puumala virus infections of HUVEC directly increased the
expression of TF on the cell surface and in the cell lysate com-
pared to controls. This resulted in drastic activation of secondary
hemostasis in our cell model during PUUV infection. Data from
a direct clotting assay on the cell monolayer gives interesting
insights in the potential mechanism behind increased throm-
bin generation seen in acute PUUV patients (Laine et al., 2010,
2014). A clear pro-coagulant state, the result of an increased
expression of TF on the surface of PUUV infected cells, resulted
in enhanced thrombin generation. Increased thrombin genera-
tion (decreased thrombin time, overall increase in prothrombin
fragments 1 + 2, antithrombin and protein C) that Laine et al.
(2010, 2014) observed in acute PUUV patients could very well
be the result of direct infection of endothelial cells and con-
comitant increased production of TF. Whether increase in TF
is a general defense response or if the virus actually beneﬁts
from TF, as is seen in certain herpesvirus infections (Pryzdial
et al., 2014), remains unknown. However, excess of TF pro-
duction during infection could lead to increased clotting and
eventually consumptive coagulopathy or even DIC, a severe
condition that is only seen in a small percentage of PUUV
patients (Laine et al., 2010), but which could be one of the
factors contributing to the hemorrhagic complications seen in
HFRS. Especially since increased TF expression has been proven
to play an important role in the pathogenesis of other viral
hemorrhagic fevers like Marburg and Ebola (Geisbert et al.,
2003a,b).
Since alterations in PAI-1 levels are related to renal distur-
bances comparable to that seen in hantavirus disease (Gong
et al., 2007; Malgorzewicz et al., 2013) and functional poly-
morphisms in PAI-1 were related to more severe disease in
acute PUUV patients (Laine et al., 2012), we also studied PAI-1
and regulators of PAI-1 activity. Infection with PUUV increases
PAI-1 production, which would in vivo lead to decreased ﬁb-
rinolysis. The ανβ3 integrin receptor plays an important role
in PAI-1/vitronectin complex formation (Zhou et al., 2003).
Increased ανβ3 expression during PUUV infection combined
with competitive binding of hantavirus with vitronectin for
ανβ3 could hypothetically lead to further alterations in PAI-1
half-life and stability. The increased level of vitronectin-PAI-1
complexes in the supernatant of PUUV infected cells further
strengthens this hypothesis. Considering that an increase in PAI-
1 and vitronectin could result in renal impairment, and even
cause a nephritis-like response, pledges for further evaluation
of interaction between ανβ3 integrin, PAI-1, vitronectin and
hantaviruses.
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